title: Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma.
abstract: OBJECTIVE
  To develop a simple extractionless method for detection of rosiglitazone in canine plasma and test the method in a pharmacokinetic study after oral administration of rosiglitazone in dogs.
  
  
  METHODS
  3 client-owned dogs with cancer.
  
  
  METHODS
  High-performance liquid chromatography-tandem mass spectrometry was performed on canine plasma. The 3 dogs with cancer in the pharmacokinetic study were assessed via physical examination and clinicopathologic evaluation and considered otherwise healthy. Food was withheld for 12 hours, and dogs were administered a single dose (4 mg/m²) of rosiglitazone. Plasma was collected at various times, processed, and analyzed for rosiglitazone.
  
  
  RESULTS
  The developed method was robust and detected a minimum of 0.3 ng of rosiglitazone/mL. Mean ± SD maximum plasma concentration was 205.2 ± 79.1 ng/mL, which occurred at 3 ± 1 hours, and mean ± SD elimination half-life was 1.4 ± 0.4 hours. The area under the plasma rosiglitazone concentration-versus-time curve varied widely among the 3 dogs (mean ± SD, 652.2 ± 351.3 ng/h/mL).
  
  
  CONCLUSIONS
  A simple extractionless method for detection of rosiglitazone in canine plasma was developed and was validated with excellent sensitivity, accuracy, precision, and recovery. The method enabled unambiguous evaluation and quantitation of rosiglitazone in canine plasma. This method will be useful for pharmacokinetic, bioavailability, or drug-drug interaction studies. Oral rosiglitazone administration was well tolerated in the dogs.
authors.affiliation: Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616, USA.
authors.forename: Sara Allstadt
authors.initials: SA
authors.lastname: Frazier
authors.forename: Daniel S
authors.initials: DS
authors.lastname: McKemie
authors.forename: Teri A
authors.initials: TA
authors.lastname: Guerrero
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Skorupski
authors.forename: Carlos O
authors.initials: CO
authors.lastname: Rodriguez
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019540:Area Under Curve; D016190:Carboplatin / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid / Q000379:methods / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D006207:Half-Life; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary; D000077154:Rosiglitazone; D012680:Sensitivity and Specificity; D053719:Tandem Mass Spectrometry / Q000379:methods / Q000662:veterinary*; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D016190:Carboplatin